Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm

Abstract

Cardiovascular disease, the major cause of death in post-menopausal women, can be reduced by re-placement of ovarian steroid hormones. To compare medroxyprogesterone with progesterone as the progestin in hormone replacement therapy from the standpoint of coronary artery vasospasm, we treated ovariectomized rhesus monkeys with physiological levels of estradiol-17β in combination with medroxyprogesterone or progesterone for four weeks. Coronary vasospasm in response to pathophysiological stimulation without injury showed that progesterone plus estradiol protected but medroxyprogesterone plus estradiol failed to protect, allowing vasospasm. We conclude that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm.

Cite this article

Miyagawa, K., Rösch, J., Stanczyk, F. et al. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 3, 324–327 (1997). https://doi.org/10.1038/nm0397-324

View full text

>> Full Text:   Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm